Lymphoma Clinical Trials

Showing 1381-1400 of 3,379 trials

Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT05768529

The study is a Phase I/II, single-arm, open-label clinical trial, and its primary objective of phase I and phase II is to evaluate the safety and efficacy of U16 Injection in the treatment of relapsed or refractory NHL,respectively.

Relapsed or Refractory Non-Hodgkin's Lymphoma

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd100 participantsStarted Mar 2023

Changsha, Hunan, China • Suzhou, Jiangsu, China

TERMINATEDPhase 1

Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors

NCT05698888

This study will test the safety, tolerability, and pharmacokinetics of VP301 in patients with relapsed or refractory multiple myeloma, lymphoma, or solid tumors.

Solid Tumors, AdultMultiple MyelomaLymphoma

Virtuoso BINco, Inc.2 participantsStarted Nov 2022

San Antonio, Texas, United States

TERMINATEDPhase 1

A Study of BTX-1188 in Subjects With Advanced Malignancies

NCT05144334

This is a multicenter, open label, nonrandomized, sequential dose escalation, multiple dose study designed to evaluate the safety, toxicity, and pharmacokinetics (PK) as well as preliminary efficacy of BTX-1188 orally administered in subjects with advanced malignancies.

Advanced Solid TumorNon Hodgkin LymphomaAcute Myeloid Leukemia

Biotheryx, Inc.8 participantsStarted Jan 2022

Duarte, California, United States • New York, New York, United States • Cincinnati, Ohio, United States +1 more locations

Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors

A Study of BTX-1188 in Subjects With Advanced Malignancies

Related Searches

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells

Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma

A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma

Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement

Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma

Go-CHOP as the Frontline Therapy for PTCL

An Individualized Physical Activity Program in Patients Over 65 Years With Hematologic Malignancies

Ketogenic Diet in Patients With Untreated Low Tumor Burden Mantle Cell Lymphoma

A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed

Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma

CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma

Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.